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Introduction
We present recent findings based on the analysis of data
from the Australasian Colorectal Cancer Family Study
and the Colon Cancer Family Registry.
De novo mutations
Carriers of a germline mutation in a DNA mismatch
repair (MMR) gene, i.e. persons with Lynch syndrome,
have substantially high risks of colorectal, endometrial,
and several other cancers. The proportion of carriers
who have de novo mutations (not inherited from either
parent) is not known. Of 261 probands (202 clinic-
based, 59 population-based) with MMR gene mutations
for whom it was possible to determine the origin of the
mutation, six (2.3%, 95%CI = 0.9–5.0%) were confirmed
as de novo and the remaining 255 (97.7%, 95%CI =
95.0–99.1%) were inherited. Of the de novo mutation
carriers, three were clinic-based probands (1.5%, 95%CI
=0 . 3 –4.5%) and three were population-based probands
(5.1%, 95%CI = 1.2–14.5%). Two were in MLH1,t h r e e
in MSH2,a n do n ei nMSH6. These mutation carriers
were recruited from family cancer clinics in Perth and
Brisbane and via the Victorian Cancer Registry, Austra-
lia, and from Mayo clinic and via the Minnesota Cancer
Surveillance System, USA. De novo MMR gene muta-
tions are uncommon causes of Lynch syndrome.
Cancer risks for non-carriers
To determine whether cancer risks for non-carriers of
an MMR gene mutation from mutation carrying families
are increased above that of the general population, we
prospectively followed a cohort of 1,029 unaffected non-
carriers. We estimated country-, age- and sex-specific
standardized incidence ratios (SIRs) of different cancers
for non-carriers. Over a median follow-up of 5 years, we
found no evidence of non-carriers having an increased
risk of any cancer, including colorectal cancer (SIR 1.02,
95%CI = 0.43 – 3.06, P = 0.97). These non-carriers had
a colonoscopy screening for every four years.
Second primary cancers
Apart from colorectal and endometrial cancers, risks of
second primary cancers after a diagnosis of first primary
colorectal cancer for MMR gene mutation carriers are
yet to be established. Using a cohort of 764 carriers who
had a diagnosis of colorectal cancer from the Colon
Cancer Family Registry, we estimated age-, sex-, coun-
try- and calendar year-specific SIRs of second primary
extracolonic cancers to compare with general popula-
tion. We observed statistical evidence for significantly
increased risks of cancers of the stomach (SIR=5.65),
small intestine (SIR=72.75), liver (SIR=5.95), kidney
(SIR=8.47), bladder (SIR=7.22), breast (SIR=1.85), brain
(SIR=4.36), bone (SIR=17.99) and haemopoietic tissue
(SIR=3.11) in both sexes, thep r o s t a t e( S I R = 2 . 0 5 )i n
males, and the endometrium (SIR=40.34) and ovary
(SIR=4.20) in females.
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